Kathryn Lipford

Statistics

Publications

Citations

H-Index

Active since

2019

Affiliations

Forma Therapeutics (United States)(Current)

Kathryn Lipford is an author at Forma Therapeutics (United States) specializing in pharmacology, isocitrate dehydrogenase mutations, and neuro-oncology clinical trials.

Publications per year

2019–2022

Publications

Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial

Macarena I. de la Fuente, Howard Colman, Mark Rosenthal et al. · Neuro-Oncology · 2022 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors

Zhou Hua, Meredeth A. McGowan, Kathryn Lipford et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 11 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–2 of 2